Symbols

AQST

Aquestive·NASDAQ

--(--)

AQST fundamentals

AQST Q4 2025 Earnings

Aquestive (AQST) released its earnings on Mar 4, 2026: revenue was 13.02M (YoY +9.67%), missed estimates; EPS was -0.26 (YoY -36.84%), missed estimates.

Revenue / YoY

13.02M

+9.67%

EPS / YoY

-0.26

-36.84%

Report date

Mar 4, 2026

AQST Earnings Call Summary for Q4,2025

FDA Path Clarified: Type A meeting expected within 30 days; resubmission guidance maintained for Q3 2026. FDA denied competitor petition, reinforcing Anaphylm's clinical strength.
Expanded Commercial Ambition: 75-rep launch team (50% increase) signals confidence in U.S. market potential. Secured $75M RTW financing extension with $5M equity investment.
Clinical Momentum: AQST-108 Phase I data highlights new indication opportunities. Anaphylm PK study includes IM epinephrine comparison to address FDA questions.
Market Growth: U.S. allergy market up 9% Q4 2025, with 90% prescriptions on auto-injectors. Anaphylm's oral delivery positioned to capture share as first non-device option.

Earnings

EPS

Revenue

Revenue & Expenses

AQST has released its 2025 Q4 earnings report, with revenue of 13.02M, reflecting a YoY change of 9.67%, and net profit of -31.86M, showing a YoY change of -86.81%. The Sankey diagram below clearly presents AQST's revenue sources and cost distribution.

Key Indicators

Aquestive (AQST) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Aquestive (AQST)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Aquestive (AQST)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Aquestive (AQST)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown